Cancer HorizonsAll NewsBlogsCaregivingDiet and ExerciseFinancialPsychosocialRecipesSexual HealthSide EffectSponsoredSurvivorship
All VideosCURE ConnectionsCURE Expert Connections®CURE Speaking OutCURE TVEducated Patient Sound BitesOn Demand: Webinars
Conference Coverage Conference Listing
CURE AdventuresCURE AwardsEducated Patient In Person EducationEducated Patient Virtual Education
Advocacy GroupsArt GalleryClinical Trial CornerHeal®PartnersPodcastsPublicationsShare Your Story
Subscribe
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
LeukemiaLeukemiaLeukemia
Lung Cancer
LymphomaLymphomaLymphomaLymphoma
Rare CancersRare Cancers
Sarcoma
Skin Cancer/Melanoma
Thyroid Cancer
Spotlight -
  • Blogs
  • Breast Cancer Webinar Series
  • Cancer Horizons
  • Clinical Trial Corner
  • Heal®
  • Publications
  • Videos
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
LeukemiaLeukemiaLeukemia
Lung Cancer
LymphomaLymphomaLymphomaLymphoma
Rare CancersRare Cancers
Sarcoma
Skin Cancer/Melanoma
Thyroid Cancer
    • Subscribe
Advertisement

Article

January 8, 2015

First Biosimilar Unanimously Recommended for Approval

Author(s):

Jason M Broderick

A Food and Drug Administration advisory committee unanimously recommended approval of EP2006, a biosimilar version of Neupogen (filgrastim).

A Food and Drug Administration (FDA) advisory committee unanimously recommended approval of a biosimilar version of Neupogen (filgrastim). If the FDA follows the recommendation, the drug, EP2006, would become the first biosimilar approved in the United States.

Filgrastim is a man-made version of granulocyte-colony stimulating factor (G-CSF), a protein that stimulates production of neutrophils. When injected into the body, filgrastim has the same effect as G-CSF, increasing an individual’s ability to fight infections.

Filgrastim is approved for chemotherapy-induced febrile neutropenia in patients with nonmyeloid malignancies, for patients with acute myeloid leukemia receiving induction or consolidation chemotherapy, and for patients receiving bone marrow transplants to treat their cancer. The drug also has approved indications to treat patients with severe chronic neutropenia and patients undergoing peripheral blood progenitor cell collection and therapy.

US law defines biosimilars as biological products demonstrated to be “interchangeable” with an FDA-licensed biological product. As part of the Affordable Care Act, an expedited approval pathway was established for biosimilars that requires less product-specific data than the FDA’s traditional regulatory channels, allowing reliance on existing efficacy and safety data for the reference product.

By voting in favor of approving EP2006, the Oncologic Drugs Advisory Committee (ODAC) asserted that the drug met the criteria established under this biosimilar pathway. Specifically, the committee is stating that EP2006 is “highly similar” to Neupogen, “notwithstanding minor differences in clinically inactive components,” and that “there are no clinically meaningful differences between EP2006 and filgrastim in terms of [purity], safety, and effectiveness.”

“We have a lot of clinical data that these are very similar compounds and pharmacokinetics and pharmacodynamics are very comparable,” says Deborah K. Armstrong, chairperson of the ODAC meeting and professor of Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

Among all the data considered for the recommendation, the key clinical study ODAC reviewed was the pivotal double-blind phase 3 PIONEER trial (EP06-302), which compared the efficacy and safety of EP2006 and US-licensed Neupogen in patients with breast cancer treated with myelosuppressive chemotherapy.

The results showed that the study met its primary endpoint. The data also showed that repeated switching at each cycle between the investigational biosimilar and Neupogen had no impact on efficacy, safety or immunogenicity.

In explaining her “yes” vote, Ginna G. Laport, clinical research director in the Division of Blood & Marrow Transplantation at Stanford University Medical Center, said the data supplied by the manufacturing company, Sandoz, was convincing. “What really moved me was the very strong evidence shown by the sponsor for biosimilarity in numerous studies.”

Sandoz already manufactures a biosimilar version of filgrastim under the brand name Zarzio in more than 40 countries. According to Sandoz, Zarzio is the leading daily G-GSF used daily in Europe.

Biosimilars have reduced healthcare costs in some of these countries, and it is hoped that it will have a similar impact in the United States. One analysis estimates that increased use of biosimilars could reduce US spending on biologics by $44 billion over the next 10 years.

Though biosimilars typically cost less than the original drugs, this will not always be the case; however, healthcare savings with biosimilars will likely be manifested in other areas, such as copay reductions and formulary decisions.

“Let me say we cannot say that the price [of EP2006] would be less [than filgrastim]—in some situations it might be a parity because of other relative terms that will come into existence…but the cost will be less to the consumer, to the payer, to the healthcare economy—otherwise it does not make sense,” Mark McCamish, global head of development at Sandoz, said at the ODAC hearing.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Picture of Dr. Jacob Sands
Picture of Dr. Xiuning Le
Picture of Suleika Jaouad
Related Content
Advertisement
Image of liver
September 11th 2025

What Patients Need to Know About Liver Cancer, From Diagnosis to Treatment

Alex Biese
The Importance of Spotting Endometrial Cancer
September 11th 2025

The Importance of Spotting Endometrial Cancer

image of a woman in pink
September 11th 2025

New Diagnosis Codes Improve Timely Access Inflammatory Breast Cancer Care

Shannon Woodworth
ROS1+ Non-Small Cell Lung Cancer: Progress in Care
September 11th 2025

ROS1+ Non-Small Cell Lung Cancer: Progress in Care

Photo of Tania Chomiak-Salvi
September 11th 2025

Perioperative Immunotherapy ‘Is The Revolution’ in NSCLC

Alex Biese
Image of ovary.
September 11th 2025

FDA Accepts New Drug Application for Relacorilant in Ovarian Cancer

Alex Biese
Related Content
Advertisement
Image of liver
September 11th 2025

What Patients Need to Know About Liver Cancer, From Diagnosis to Treatment

Alex Biese
The Importance of Spotting Endometrial Cancer
September 11th 2025

The Importance of Spotting Endometrial Cancer

image of a woman in pink
September 11th 2025

New Diagnosis Codes Improve Timely Access Inflammatory Breast Cancer Care

Shannon Woodworth
ROS1+ Non-Small Cell Lung Cancer: Progress in Care
September 11th 2025

ROS1+ Non-Small Cell Lung Cancer: Progress in Care

Photo of Tania Chomiak-Salvi
September 11th 2025

Perioperative Immunotherapy ‘Is The Revolution’ in NSCLC

Alex Biese
Image of ovary.
September 11th 2025

FDA Accepts New Drug Application for Relacorilant in Ovarian Cancer

Alex Biese
About Us
Advertise / Support
Editorial Board
Contact Us
CancerNetwork.com
TargetedOnc.com
OncLive.com
OncNursingNews.com
Terms & Conditions
Privacy
Do Not Sell My Information
Contact Info

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.